C
Christopher Brown
Researcher at Seattle Children's Research Institute
Publications - 9
Citations - 978
Christopher Brown is an academic researcher from Seattle Children's Research Institute. The author has contributed to research in topics: Antigen & CD8. The author has an hindex of 6, co-authored 9 publications receiving 670 citations.
Papers
More filters
Journal ArticleDOI
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Rebecca Gardner,Rebecca Gardner,Olivia Finney,Colleen Annesley,Colleen Annesley,Hannah Brakke,Corinne Summers,Corinne Summers,Kasey J. Leger,Marie Bleakley,Marie Bleakley,Christopher Brown,Stephanie Mgebroff,Karen S. Kelly-Spratt,Virginia Hoglund,Catherine Lindgren,Assaf P. Oron,Daniel Li,Stanley R. Riddell,Stanley R. Riddell,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen,Michael C. Jensen +24 more
TL;DR: These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis.
Journal ArticleDOI
Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility.
Annette Künkele,Agne Taraseviciute,Agne Taraseviciute,Agne Taraseviciute,Laura S. Finn,Adam Johnson,Carolina Berger,Carolina Berger,Olivia Finney,Cindy A. Chang,Lisa S. Rolczynski,Christopher Brown,Stephanie Mgebroff,Michael Berger,Julie R. Park,Michael C. Jensen,Michael C. Jensen +16 more
TL;DR: The preclinical assessment of the CE7 epitope on CD171 supports its utility and safety as a CAR T-cell target for neuroblastoma immunotherapy.
Journal ArticleDOI
Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia
Rebecca Gardner,Colleen Annesley,Olivia Finney,Corinne Summers,Adam J. Lamble,Julie Rivers,Kaelin Crews,Lauren Huang,Christopher Brown,Stephanie Mgebroff,Catherine Lindgren,Karen Spratt,Josh Gustafson,Adam Johnson,Julie R. Park,Michael C. Jensen +15 more
TL;DR: The primary objectives were to determine the feasibility of manufacturing products with dual specificity, to assess the safety of the cryopreserved product infusion, and to describe the full toxicity profile.
Journal ArticleDOI
Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
Colleen Annesley,Colleen Annesley,Rebecca Gardner,Ashley Wilson,Corinne Summers,Corinne Summers,Corinne Summers,Adam J. Lamble,Adam J. Lamble,Julie Rivers,Julie Rivers,Qian Vicky Wu,Adam Brand,Adam Johnson,Karen Spratt,Stephanie Mgebroff,Christopher Brown,Catherine Lindgren,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen +21 more
TL;DR: It is hypothesized that episodic antigen exposure using CD19t T cell antigen presenting cells (T-APCs) can trigger CD19 CAR T cell proliferation and re-activation in vivo, resulting in more durable CAR Tcell persistence and diminished risk of CD19+ relapse.
Journal ArticleDOI
Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion
Annette Künkele,Annette Künkele,Christopher Brown,Adam Beebe,Stephanie Mgebroff,Adam Johnson,Agne Taraseviciute,Agne Taraseviciute,Agne Taraseviciute,Lisa S. Rolczynski,Cindy A. Chang,Olivia Finney,Julie R. Park,Julie R. Park,Michael C. Jensen +14 more
TL;DR: It is concluded that cryopreserved PBSCs procured via standard methods during early treatment can serve as an alternative starting source for CAR-T cell manufacturing, extending the options for heavily treated patients.